Loop Diuretic Therapy in Acutely Decompensated Heart Failure

Launched by UNIVERSITY OF SIENA · Dec 18, 2015

Keywords

ClinConnect Summary

This clinical trial is studying the best way to give a medicine called furosemide, which helps remove extra fluid from the body, to people who are hospitalized with acute heart failure—a sudden worsening of heart problems that causes symptoms like shortness of breath, swelling, and tiredness. The study compares giving the medicine continuously through a drip versus giving it in separate doses to see which method works better for patients.

To join the study, patients need to be adults diagnosed with acute heart failure, showing symptoms such as difficulty breathing or swelling, and have a specific blood test (called BNP) that is higher than 100, indicating heart stress. People who have very low blood pressure, severe kidney problems, recent heart attacks, or certain other serious illnesses are not eligible. Participants will receive the furosemide treatment while in the hospital, and doctors will carefully observe how the different methods affect their recovery. This study aims to find the safest and most effective way to use this important medicine to help people feel better faster.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years;
• • Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on chest radiography, jugular vein dilatation, or a third heart sound);
• • Blood BNP \> 100 pg/mL;
• • ADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous; LVEF: Left Ventricular Ejection Fraction.
• Exclusion Criteria:
• • Patients who receive more than 40 mg of IV furosemide;
• • End-Stage renal disease or renal replacement therapy;
• • Recent myocardial infarction (within thirty days of screening);
• • Systolic blood pressure \< 80 mmHg;
• • Creatinine levels \> 4 mg/dL;
• • Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic diseases.